Struggling With Stubborn Weight After 40? Medical Weight Loss Options in Florida
Weight management after 40 can feel different than it did in your 20s or 30s. If the scale keeps climbing despite your efforts, you're not alone—and the explanation isn't necessarily a lack of willpower.
Changes in activity, sleep, muscle mass, medications, appetite, and metabolic health can all influence body weight. For some people, nutrition and lifestyle adjustments are enough. Others may benefit from a medical evaluation and evidence-based treatment options.
At Apex Coastal Wellness, we believe weight management should focus on your overall health, not just a number on the scale. Here's what the research says about stubborn weight after 40 and the medical weight loss options available through Florida telehealth.
Why Can Weight Become Harder to Manage After 40?
There isn't one universal reason people gain weight in midlife. Several factors can overlap.
Changes in muscle mass and activity. Adults can gradually lose muscle with aging, particularly without regular resistance exercise. Because muscle contributes to energy expenditure, changes in body composition and daily activity can affect how many calories the body uses.
Sleep and stress. Inadequate sleep and ongoing stress can affect appetite, food choices, energy, and the ability to maintain consistent routines.
Medications and health conditions. Some medications can contribute to weight gain. Conditions such as hypothyroidism, sleep apnea, and depression may also influence weight or make weight management more difficult. A clinician can help determine whether further evaluation is appropriate.
Hormonal changes. Menopause can contribute to changes in body composition and fat distribution. In men and women, however, weight gain alone does not establish a hormone deficiency. Hormone testing and treatment should be based on symptoms, clinical assessment, and appropriate laboratory findings—not age or weight alone.
Appetite and biology. Weight regulation involves complex signals between the brain, digestive system, and fat tissue. After weight loss, biological adaptations can increase hunger and make maintaining weight loss more difficult. This is one reason obesity is increasingly understood as a chronic, relapsing condition rather than simply a matter of willpower.
When Should You Consider Medical Weight Loss?
A medical evaluation may be useful if you've repeatedly lost and regained weight, have weight-related health concerns, or are unsure which approach is appropriate for you.
A clinician may review your weight history, blood pressure, medications, sleep, eating patterns, activity level, and relevant medical history. Depending on your circumstances, laboratory testing may help assess conditions such as diabetes, prediabetes, thyroid disease, or abnormal cholesterol.
Prescription weight-management medication may be appropriate for some adults. Under commonly used FDA prescribing criteria, medications for chronic weight management may be considered for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition, alongside reduced-calorie nutrition and increased physical activity. Individual products have their own prescribing information and eligibility considerations.
BMI is a screening tool, not a complete measure of health. Treatment decisions should account for your overall clinical picture, preferences, risks, and goals.
What Are the Medical Weight Loss Options in Florida?
Medical weight management can include nutrition and activity planning, behavioral support, evaluation of contributing conditions, and prescription medication when clinically appropriate.
Two medications that have received considerable attention in obesity research are semaglutide and tirzepatide.
Semaglutide for Weight Management
Semaglutide is a medication that acts on the glucagon-like peptide-1 (GLP-1) receptor. It helps regulate appetite and food intake and can increase feelings of fullness.
In the landmark STEP 1 trial, published in The New England Journal of Medicine in 2021, 1,961 adults with overweight or obesity without diabetes received once-weekly semaglutide 2.4 mg or placebo, alongside lifestyle intervention. At 68 weeks, the average change in body weight was approximately −14.9% with semaglutide compared with −2.4% with placebo.
These are group averages from a clinical trial, not a prediction of what any one person will lose. Individual responses vary, and treatment requires ongoing medical oversight.
Tirzepatide for Weight Management
Tirzepatide acts on both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. These pathways influence appetite, food intake, and glucose regulation.
In the SURMOUNT-1 trial, published in The New England Journal of Medicine in 2022, 2,539 adults with obesity or overweight plus a weight-related complication, without diabetes, received tirzepatide or placebo alongside lifestyle intervention. At 72 weeks, average weight reduction was approximately 15.0%, 19.5%, and 20.9% with the 5 mg, 10 mg, and 15 mg doses, respectively, compared with 3.1% with placebo.
Results were dose-dependent at the group level, but the highest dose is not automatically the right choice for every patient. Dose escalation, tolerability, contraindications, and individual treatment goals matter.
What Do These Studies Mean for You?
These landmark trials show that prescription medications can produce clinically meaningful weight reduction for appropriately selected patients when combined with lifestyle intervention.
However, the trials should not be used to promise a particular result or to compare medications as if they were tested head-to-head under identical conditions. Participants, study designs, treatment duration, and other factors differ.
The best treatment is the one that fits a person's health needs, safety profile, preferences, and ability to continue care.
Is Medical Weight Loss About More Than the Scale?
It can be. Excess weight may be associated with high blood pressure, abnormal cholesterol, type 2 diabetes, sleep apnea, fatty liver disease, joint problems, and cardiovascular risk. Appropriate weight management may help improve some of these conditions, depending on the individual.
The SELECT trial, published in The New England Journal of Medicine in 2023, studied semaglutide 2.4 mg in adults aged 45 and older with overweight or obesity, established cardiovascular disease, and no diabetes. Over a mean follow-up of approximately 40 months, major cardiovascular events occurred in 6.5% of participants receiving semaglutide and 8.0% receiving placebo—a 20% relative reduction in the trial's primary composite outcome.
Important context: SELECT studied a specific population with established cardiovascular disease. Its findings should not be generalized to everyone seeking weight loss or interpreted as proof that every patient taking a weight-management medication will have fewer cardiovascular events.
What Happens When You Stop Weight Loss Medication?
This is an important question to discuss before beginning treatment.
In an extension of the STEP 1 trial, researchers followed a subset of participants after semaglutide and the structured lifestyle intervention were discontinued. During the following year, participants regained an average of about two-thirds of the weight they had previously lost.
This finding supports the understanding that obesity may require long-term management. It does not mean everyone will regain the same amount, but it does mean patients should understand the potential for weight regain before stopping treatment.
Medication decisions should include a plan for follow-up, nutrition, physical activity, and long-term weight maintenance. For some patients, continued medication may be appropriate; for others, a different strategy may be needed.
Are Semaglutide and Tirzepatide Safe?
No prescription medication is appropriate for everyone. Semaglutide and tirzepatide can cause gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort. More serious concerns can include gallbladder disease, pancreatitis, dehydration-related kidney problems, and other product-specific risks.
These medications carry a boxed warning regarding thyroid C-cell tumors observed in rodents. They should not be used in people with a personal or family history of medullary thyroid carcinoma or in people with multiple endocrine neoplasia syndrome type 2 (MEN2). The full prescribing information includes additional warnings, precautions, contraindications, and instructions for use.
Pregnancy, planned pregnancy, other medications, prior medical conditions, and surgical or anesthesia plans may affect treatment decisions. Your clinician should review the applicable prescribing information and your individual circumstances before prescribing.
Use only medication obtained through legitimate, appropriately regulated channels. Compounded drugs are not FDA-approved products, and their quality, safety, and effectiveness are not reviewed by the FDA in the same way as an approved drug. Compounded medication should not be assumed to be interchangeable with an FDA-approved product.
What About Nutrition, Exercise, and Muscle Preservation?
Medication, when appropriate, works best as part of a broader care plan. The goal is not simply to reduce body weight; it is to support health, function, and sustainable habits.
Useful foundations include:
Prioritize adequate protein and nutrient-dense foods. Individual protein needs vary, particularly for people with kidney disease or other medical considerations.
Include resistance exercise when appropriate. Strength training can help preserve muscle during weight loss, alongside regular aerobic activity.
Build consistent routines. Sleep, meal planning, hydration, and activity can all support long-term health.
Monitor more than body weight. Blood pressure, waist circumference, metabolic markers, energy, mobility, and other health goals may provide useful context.
Plan for maintenance. Discuss follow-up, side effects, medication access, and what happens if treatment changes.
A sustainable plan should fit your health status and real life—not require perfection.
Florida Medical Weight Loss Through Telehealth
A virtual visit can be a convenient way to begin discussing your weight-management goals, health history, and potential treatment options when you are eligible for telehealth care.
At Apex Coastal Wellness, our approach starts with understanding your goals and determining whether our services may be appropriate. If laboratory testing or a more detailed clinical evaluation is recommended, we'll explain the proposed next steps and associated costs before you decide whether to proceed.
If prescription treatment is being considered, eligibility, risks, benefits, alternatives, and ongoing monitoring must be reviewed. A consultation does not guarantee a prescription, and treatment recommendations depend on clinical judgment and applicable requirements.
The Bottom Line
If weight has become harder to manage after 40, you don't have to guess at the reason or navigate every option alone. Aging, sleep, activity, medications, hormones, and metabolic health may all play a role, and no single explanation fits everyone.
Evidence from landmark trials shows that semaglutide and tirzepatide can help eligible patients achieve meaningful weight loss, but these medications require individualized prescribing, safety monitoring, and a long-term plan.
The best next step is a thoughtful assessment of your health, goals, and options—not a promise of a specific number on the scale.
Jeff Schnur, MSN, APRN, FNP-BC
Apex Coastal Wellness
Outlast the Day.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232. https://doi.org/10.1056/NEJMoa2307563
Wilding JPH, Batterham RL, Davies M, et al. Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. https://doi.org/10.1111/dom.14725
